The FDA’s CTGTAC voted that the data from the IGNYTE trial are evaluable and clinically meaningful for RP1/nivolumab in advanced cutaneous melanoma.
|Articles|August 25, 2022
Treating Patients with Gastric Cancer
This publication highlights a scientific interchange held to evaluate recent data on therapeutic options for advanced gastric and gastroesophageal cancers, explore evidence-based therapy approaches and sequencing strategies in patients with HER2+ disease, and discuss methods to optimize treatment selection and management.
Related to this article
Dana-Farber Cancer Institute researchers studied alveolar rhabdomyosarcoma, a cancer with few treatment options, to identify new treatment vulnerabilities.
The FDA has granted priority review to subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck cancer.
The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.
Leukocyte interleukin injection improved OS in patients with oral cancer expressing low tumor PD-L1 levels.
Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.
Two decades of biomarker-driven progress have reshaped lung cancer management, but late diagnosis, unequal treatment access, and underfunding remain
The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
Precision Advances Have Transformed Lung Cancer Care, But Key Barriers Persist
4
FDA Awards Orphan Drug Designation to Enzomenib for ALL
5